Health Care • Medical Specialities
$5.87 ▼ -0.41
(-6.53%)
MKT CAP: $415.8M • VOL: 96.2K
52W L $2 52W H $16
YDES // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $596.8K | $510.4K | $350.1K |
| YoY Revenue Growth % | +16.9% | +45.8% | — |
| Gross Profit | $167.4K | $155.4K | — |
| Gross Margin % | 28.1% | 30.4% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$5.3M | -$1.5M | -$9.8K |
| Operating Margin % | -80.0% | -80.0% | -2.8% |
| Net Income (GAAP) | -$8.3M | -$1.4M | $13.6K |
| EBITDA (Normalized) | -$4.1M | -$1.4M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$6.6M | -$1.2M | -$55.7K |
| Capital Expenditures (CapEx) | $1.4M | $74.9K | — |
| Free Cash Flow (FCF) | -$8.0M | -$1.3M | -$55.7K |
| FCF Margin % | -80.0% | -80.0% | -15.9% |
| Return on Invested Capital (ROIC %) | -45.0% | -33.4% | — |
| Cash & Short-Term Equivalents | $6.0M | $3.1M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | -$2.9M | $6.6M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR YDES.